KPP Advisory Services LLC Purchases 594 Shares of Pfizer Inc. (NYSE:PFE)

KPP Advisory Services LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 6.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,232 shares of the biopharmaceutical company’s stock after buying an additional 594 shares during the quarter. KPP Advisory Services LLC’s holdings in Pfizer were worth $245,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. Quarry LP bought a new position in shares of Pfizer during the second quarter worth approximately $31,000. Czech National Bank grew its stake in shares of Pfizer by 6.9% in the third quarter. Czech National Bank now owns 1,154,366 shares of the biopharmaceutical company’s stock valued at $33,407,000 after acquiring an additional 74,737 shares in the last quarter. GAMMA Investing LLC raised its stake in Pfizer by 48.9% in the 3rd quarter. GAMMA Investing LLC now owns 39,904 shares of the biopharmaceutical company’s stock worth $1,155,000 after purchasing an additional 13,097 shares in the last quarter. Diversified Trust Co grew its position in shares of Pfizer by 33.8% during the 3rd quarter. Diversified Trust Co now owns 113,505 shares of the biopharmaceutical company’s stock worth $3,285,000 after purchasing an additional 28,658 shares in the last quarter. Finally, Smith Anglin Financial LLC increased its holdings in shares of Pfizer by 2.2% during the third quarter. Smith Anglin Financial LLC now owns 22,521 shares of the biopharmaceutical company’s stock worth $652,000 after purchasing an additional 495 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Guggenheim cut their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Bank of America restated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.23 on Tuesday. The firm has a market cap of $148.62 billion, a PE ratio of 35.44, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The firm’s fifty day moving average is $26.27 and its 200-day moving average is $27.85. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.56%. Pfizer’s dividend payout ratio is 232.44%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.